Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
Kathy S. Albain(Loyola University Chicago), Joyce O’Shaughnessy(Baylor University Medical Center), A Płużańska(Fundación Instituto Valenciano de Oncología), G. Calderillo-Ruiz(Fundación Instituto Valenciano de Oncología), Johann Petrus Jordaan(Fundación Instituto Valenciano de Oncología), Lorinda Simms(Eli Lilly (United States)), Allen S. Melemed(Fundación Instituto Valenciano de Oncología), Jose M. Reyes-Vidal(Fundación Instituto Valenciano de Oncología), Shona Nag(Max Super Speciality Hospital), Antonio Llombart‐Cussac(MedSIR (Spain)), Jagdev Singh Sekhon(Fundación Instituto Valenciano de Oncología), Janusz Rolski(Fundación Instituto Valenciano de Oncología)
Cited by 422
Related Papers
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k